Lundbeck shelves Alzheimer’s drug

All hopes seem to be lost for Lundbeck with Alzheimer’s candidate idalopirdine, as the last two phase III studies have been as disappointing as the first and the group has decided not to pursue a regulatory path for the drug.

Lundbeck CEO, Kåre Schultz

Log in to read our articles

Welcome to MedWatch. A part of our content is exclusive and reserved for our users.

Try us free for 14 days

Try a trial subscription for free access to our quality journalism

Frontpage right now

MedWatch-indeks: Endnu en tung uge for biotekaktierne

Nedturen ser ud til at fortsætte for de danske biotekaktier, som alle oplevede kursfald i uge 47. Novo Nordisk ender for en efterhånden sjælden gangs skyld på toppen i MedWatch-indekset, efter at have givet markedet tiltro til fremtiden på sin kapitalmarkedsdag.

Latest Top picks in English

Related articles